Mergers & Acquisitions - Licensing, Financial

Filter

Current filters:

LicensingFinancial

Popular Filters

Astellas links with Mitokyne on mitochondria-related therapies

Astellas links with Mitokyne on mitochondria-related therapies

07-10-2013

Japanese drug major Astellas Pharma and USA-based start-up Mitokyne have entered into an exclusive R&D…

Astellas PharmaFinancialLicensingMergers & AcquisitionsMitokynePharmaceuticalResearch

First-half 2013 sees fall in licensing, says Evaluate

20-09-2013

Despite a positive start to the year characterized by healthy initial public offering (IPO) activity…

FinancialLicensingMergers & AcquisitionsPharmaceutical

Life Sciences IPOs have biggest month - May - in 13 years, reports Burrill

07-06-2013

A total of eight life sciences companies went public on US exchanges in May, the busiest month for initial…

BiotechnologyFinancialLicensingMergers & AcquisitionsPharmaceutical

Two life sciences IPOs and strengthening markets offer encouragement to Biotech sector

04-04-2013

Two companies focused on infectious disease successfully completed initial public offerings (IPOs) in…

BiotechnologyFinancialLicensingMergers & Acquisitions

Lundbeck takes 5% stake in Biotie; amends Selincro licensing deal

07-09-2012

Danish CNS drug specialist Lundbeck A/S (LUND: DC) said this morning that it has made an investment of…

BiotechnologyBiotie TherapiesFinancialLicensingLundbeckMergers & AcquisitionsNeurologicalPharmaceuticalSelincro

Biotech deal-making off to a strong start in 2012, says Burrill

02-02-2012

Swiss drug major Roche's hostile $5.7 billion bid for the tools and sequencing systems company Illumina…

BiotechnologyFinancialLicensingMergers & AcquisitionsNorth America

Angiotech opts out of cardiovascular cell therapy program with Athersys

15-11-2011

Regenerative medicines firm Athersys (Nasdaq: ATHX) says that Canada’s Angiotech Pharmaceuticals…

AngiotechAthersysBiotechnologyFinancialLicensingMergers & Acquisitions

Company Spotlight

Eleven Biotherapeutics

Eleven Biotherapeutics

Back to top